Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved crawled date : 2021 - 09 - 22 save search
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | News | $92.61 -0.51% 430K
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $52.46 -0.49% 330K
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
CMS Approves Clover Health's Expansion Plans for 2022
Published: 2021-09-22 (Crawled : 13:15) - globenewswire.com
CLOV | $0.6407 3.06% 1M
|
|
| O: 2.83%
H: 1.75%
C: -1.38%
expansion approval health
SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years
Published: 2021-09-22 (Crawled : 13:00) - globenewswire.com
SCYX | $1.45 2.11% 32K
|
Health Technology
|
| O: 3.33%
H: 1.69%
C: -3.56%
fda therapy injection infections
Cowen Board of Directors Approves Increase in Share Repurchase Program to $50 million
Published: 2021-09-22 (Crawled : 12:15) - globenewswire.com
COWN | $38.99 0.31% 0.0% 0
|
Finance
|
| O: 2.62%
H: 2.89%
C: 0.91%
approval
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | $13.215 0.49% 210K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $26.975 -2.41% 150K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Columbia Banking System and Bank of Commerce Holdings Announce Shareholder and Regulatory Approvals and Anticipated Merger Closing Date
Published: 2021-09-22 (Crawled : 03:00) - prnewswire.com
COLB | $17.88 2.23% 220K
|
Finance
|
| O: 1.45%
H: 2.08%
C: 0.18%
merge approval
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
INCY | $52.46 -0.49% 330K
|
Health Technology
|
| O: -0.21%
H: 1.43%
C: 0.41%
treatment fda fda approval dermatitis approval atopic dermatitis
Gainers vs Losers
| 83% | 17% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0504 35.12% 300M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.